

PROGRAM



Bio-Neuroscience

Amsterdam, 25th-27th February, 2025

THE GLOBAL SUMMIT FOR LEADERS AND
DECISION-MAKERS IN CNS NEUROSCIENCES
DRUG DEVELOPMENT

- Key Opinion Leaders
- Startups Founders
- C-level Executives
- Industry Executives
- Investors



INSIGHT-ACCESS - ENGAGEMENT - IMPACT

AN INITIATIVE OF



CO-ORGANIZED WITH



DAY 1

TUESDAY 25 FEB. 2025



Bio-Neuroscience

15:00

COFFEE & REGISTRATION

16:00

Summit Welcome & Opening Session

Christian J Suojanen

CEO – Broadreach Global

Andrea Soto Padilla

Amsterdam Neuroscience

16:30

Neuroscience Funding & European Policy – The EU Biotech Act, Pharma Package, And Innovation In CNS Neuroscience

Moderator: Christian J Suojanen, CEO – Broadreach Global

Alexander Natz

Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Fred Destrebecq

Executive Director, European Brain Council (EBC)

Jacopo Andreose

CEO – Angelini Pharma

Mark Treherne

Angel Investor, Serial Entrepreneur

17:15

The Impact Of Successful Drug Development

A patient - clinician conversation

Dr. Brigit de Jong

Neurologist Amsterdam University Medical Center

Patient representative

to be announced

18:00

End Of Day Remarks

18:00

WELCOME RECEPTION & NETWORKING



08:15

REGISTRATION OPENS, COFFEE & NETWORKING

09:00

Opening Remarks & Inauguration

Christian J Suojanen	CEO – Broadreach Global
Pieter van Bokhoven	Chief Scientific Officer - IXA Amsterdam Neuroscience UMC

09:15

Keynote I – The Quest To Make A Real Difference In Serious Mental Illness

Husseini K Manji	MD, FRCPC, Prof - Oxford University, Co-chair - UK Government Mental Health Mission
------------------	--

09:45

Discussion Panel - Advancing Psychiatric Drug Development

Moderator: Andrea Soto Padilla, Business Development - Amsterdam UMC

Husseini K Manji	MD, FRCPC, Prof - Oxford University, Co-chair - UK Government Mental Health Mission
Francesca Cormack	Chief Scientist - Cambridge Cognition
Tarek Samad	Senior Vice President & Global Head of Research - Lundbeck
Nawal Roy	Founder & CEO – Holmusk
Joachim Scholpp	Global Head Translational Medicine CNS & Emerging Areas - Boehringer Ingelheim

10:45

NETWORKING COFFEE BREAK

11:15

Patient Driven Innovation

Moderator: Juan Carlos Lopez, Managing Director, Haystack Science

Sunitha Malepati	Founder - Buffalo Initiative, Vice President - CACNA1A Foundation
Allyson Berent	CSO - Foundation for Angelman Syndrome Therapeutics (FAST)
Charlene Rigby	President & Founding Board Member - STXBP1 Foundation
Yael Weiss	CEO – Mahzi Therapeutics



12:15

Investor Session - Leading Early-Stage Neuroscience Investors. What CEOs Need To Know

Moderator: Christian J. Suojanen, CEO – Broadreach Global

Claire Leurent	Managing Director – AbbVie Ventures
Raúl Martín-Ruiz	Partner - Ysios Capital
Thomas Michael Thestrup	Senior Principal - Angelini Ventures
Clara Campàs	Managing Partner & Co-Founder - Asabys Partners
Hakan Goker	Managing Director, Head of Healthcare & Life Sciences - M-Ventures

13:15

LUNCH & NETWORKING BREAK

14:15

Fireside Chat – The Journey From Idea To Exit

Moderator: Kees Been, CEO, Kynexis Therapeutics

Steve Brannan	(former) Chief Medical Officer, Karuna Therapeutics
---------------	---

15:00

COMPANY PITCH SESSION

Selected companies present to an industry & investor panel

15:45

NETWORKING COFFEE BREAK

16:15

A.I. And Big Data In CNS Neuroscience Drug Discovery. Beyond Repurposing To New Frontiers In Innovation

Tushar Satav	Chief Executive Officer – Keystonemab
Thomas M. Kaiser	Chief Scientific Officer - Avicenna Biosciences, Inc

17:00

COMPANY PITCH SESSION

Selected companies present to an industry & investor panel

17:45

END OF DAY I & NETWORKING RECEPTION



08:15

REGISTRATION OPENS, COFFEE & NETWORKING

09:00

Opening Remarks

09:15

Keynote II – State Of The Art In BBB Penetration And Delivery Technologies

Robert Thorne

Denali Fellow - Denali Therapeutics,
Adjunct Associate Professor - University of Minnesota,
President - International Brain Barriers Society (IBBS)

10:00

Clinical Trial Design In ND Disease – Approaches In Alzheimer’s Disease, Larger Indications And ALS (And Orphan Indications)

Moderator: Martien Kas, President - European College of NeuroPsychopharmacology (ECNP)

Philip Scheltens

Head, Dementia Fund, Partner - EQT Life Sciences

Leonard van den Berg

Chair - TRICALS (ALS Trial Research)

10:45

NETWORKING COFFEE BREAK

11:15

Beyond Traditional Approaches In Neurodegeneration

Moderator: Stacie Weninger, Executive Director – F-Prime Biomedical Research Initiative

John Nieland

CSO, 2N Pharma ApS

Klaus Dugi

Klaus Dugi, CEO - Vandria SA

Stevin Zorn

President & CEO - MindImmune Therapeutics

12:00

COMPANY PITCH SESSION

Selected companies present to an industry & investor panel



12:45

LUNCH & NETWORKING BREAK

13:45

Growth Company Panel: Executing The Development Plan In Changing Market Conditions

Moderator: Christian J Suojanen, CEO – Broadreach Global

Rita Balice Gordon	CEO – Muna Therapeutics
Vikas Sharma	Chief Business Officer - QurAlis
Bruce Leuchter	CEO - Neurvati and GRIN Therapeutics
Sander van Deventer	Chief Executive Officer, VectorY (or colleague)

14:45

Industry Panel - Partnering With Industry

Moderator: Christian J Suojanen, CEO – Broadreach Global

Hugh Nuthall	Executive Director, Search & Evaluation, Neuroscience - Eli Lilly
Jan Klatt	Senior Vice President, Head, Development Unit Neurology & Immunology - Merck KGaA
Steven Biesmans	Principal - UCB Ventures
Pablo Sardi	Global Head, Rare & Neurologic Diseases Therapeutic Area - Sanofi

15:45

Bio-Neuroscience Awards

Company Pitch Awards

16:00

Closing Remarks

16:15

END OF SUMMIT - NETWORKING RECEPTION



STRATEGIC PARTNERS

Gold Sponsors



Silver Sponsors



Bronze Sponsors



Partners

Organized by:



Co-Organizer:

